Gabapentin for the Treatment of Neuroleptic-Induced Tremor

• Status: Terminated
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

We will attempt to establish whether gabapentin as compared with placebo will reduce the severity of tremors caused by the use of antipsychotic medications. Baseline severity of tremor will be measured using both clinical ratings and ratings obtained with an instrument designed to measure tremor, giving more objective evidence of tremor frequency and severity.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Minneapolis Veterans Affairs Medical Center
• Collaborator: Pfizer
• Treatments: Antipsychotic Agents; Gabapentin; gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

• Veterans 18 and older with an observable tremor judged to be caused by exposure to antipsychotics

Exclusion Criteria:

• Concomitant use of other anticonvulsants, L-Dopa, cocaine, amphetamines, or other tremorogenic agents excepting SSRIs, TCAs.

• Current suicidality, severe psychosis, inability to sign informed consent or to cooperate with study procedures.

• Current use of gabapentin or exposure to gabapentin in the past 2 years.

• Women who are pregnant, or not using adequate birth control.